2. Search Result
Search Result
Results for "

Type II inhibitor

" in MedChemExpress (MCE) Product Catalog:

200

Inhibitors & Agonists

1

Biochemical Assay Reagents

9

Peptides

8

Inhibitory Antibodies

11

Natural
Products

3

Recombinant Proteins

10

Isotope-Labeled Compounds

2

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15465
    KN-93
    Maximum Cited Publications
    95 Publications Verification

    		 CaMK Autophagy Cancer
    KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM.
    KN-93
  • HY-12075
    LY2109761
    65+ Cited Publications

    		 TGF-β Receptor Autophagy Cancer
    LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively.
    LY2109761
  • HY-13635
    Finasteride
    4 Publications Verification

    MK-906

    		 Environmental Pollutants 5 alpha Reductase Cancer
    Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride
  • HY-13955
    Telmisartan
    15+ Cited Publications

    BIBR 277

    		 Angiotensin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
    Telmisartan
  • HY-16742
    Gepotidacin
    10+ Cited Publications

    GSK2140944

    		 Antibiotic Bacterial Topoisomerase Infection
    Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor.
    Gepotidacin
  • HY-18960
    CHZ868
    5+ Cited Publications

    		 JAK Cancer
    CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.
    CHZ868
  • HY-112089
    Naporafenib
    5 Publications Verification

    LXH254

    		 Raf p38 MAPK Bcr-Abl Cancer
    Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively .
    Naporafenib
  • HY-N0433
    Astragaloside II
    1 Publications Verification

    Astrasieversianin VIII

    		 Autophagy Interleukin Related HIF/HIF Prolyl-Hydroxylase SOD NF-κB Inflammation/Immunology Endocrinology Cancer
    Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis .
    Astragaloside II
  • HY-13525
    CP-91149
    5+ Cited Publications

    		 Biochemical Assay Reagents Metabolic Disease Cancer
    CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study .
    CP-91149
  • HY-10326
    GW788388
    15+ Cited Publications

    		 TGF-β Receptor Cancer
    GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
    GW788388
  • HY-15465B
    KN-93 phosphate
    Maximum Cited Publications
    95 Publications Verification

    		 CaMK Autophagy Cancer
    KN-93 phosphate is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM .
    KN-93 phosphate
  • HY-108355
    R59949
    1 Publications Verification

    		 PKC Cancer
    R59949 is a pan diacylglycerol kinase (DGK) inhibitor with an IC50 of 300 nM. R59949 strongly inhibits the activity of type I DGK α and γ and moderately attenuates the activity of type II DGK θ and κ. R59949 activates protein kinase C (PKC) by enhancing the levels of the endogenous ligand diacyl glycerol .
    R59949
  • HY-109500
    Masoprocol

    meso-Nordihydroguaiaretic acid; meso-NDGA

    		 Lipoxygenase Metabolic Disease Cancer
    Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .
    Masoprocol
  • HY-E70562
    Mucinase StcE

    		Bacterial Infection Cancer
    Mucinase StcE is a zinc metalloproteinase belonging to the M66 family, which is secreted by enterohemorrhagic Escherichia coli via the type II general secretion pathway. Mucinase StcE specifically recognizes and cleaves the 'T*XT' motif in mucin-type glycoproteins with α-O-glycans (such as MUC2, Mucin 7, Glycoprotein 340, CD45, CD43, C1 Esterase Inhibitor (HY-P991629), etc.). By degrading the mucus layer to reduce its viscosity, inhibiting complement cascade activation, and localizing complement regulatory factors to the cell membrane, Mucinase StcE helps bacteria penetrate the mucosal barrier, adhere to host cells, and evade immune clearance. Mucinase StcE can serve as a mucin-specific proteolytic tool for research on mucinous carcinomas derived from the colon, esophagus, and salivary glands .
    Mucinase StcE
  • HY-15004
    AUZ 454
    5+ Cited Publications

    K03861

    		 CDK Cancer
    AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.
    AUZ 454
  • HY-128348
    PK68

    		RIP kinase Inflammation/Immunology Cancer
    PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .
    PK68
  • HY-15465A
    KN-93 hydrochloride
    Maximum Cited Publications
    95 Publications Verification

    		 CaMK Autophagy Cancer
    KN-93 hydrochloride is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM.
    KN-93 hydrochloride
  • HY-P10486
    AIP-II

    		Bacterial Infection
    AIP-II is a cyclic peptide signaling molecule for quorum sensing, which is produced by Staphylococcus aureus. AIP-II potently inhibits AgrC-III in Methicillin (HY-121544)-resistant type III Staphylococcus aureus strain AH1747, with an IC50 of 0.532 nM. AIP-II binds to the AgrC-II receptor and regulates virulence gene expression in Staphylococcus aureus .
    AIP-II
  • HY-103195
    NKY80
    2 Publications Verification

    		 Adenylate Cyclase Metabolic Disease
    NKY80 is a potent, selective and non-competitive adenylyl cyclase (AC) type V isoform inhibitor with IC50s of 8.3 µM, 132 µM and 1.7 mM for type V, III and II, respectively. NKY80 is a non-nucleoside quinazolinone and regulates the AC catalytic activity in heart and lung tissues .
    NKY80
  • HY-101267
    CHMFL-BMX-078
    3 Publications Verification

    CHMFL-BMX 078

    		 BMX Kinase Cancer
    CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
    CHMFL-BMX-078
  • HY-111507
    PDGFRα kinase inhibitor 1
    1 Publications Verification

    		 PDGFR Cancer
    PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively .
    PDGFRα kinase inhibitor 1
  • HY-76938
    Actarit

    4-Acetylaminophenylacetic acid; MS-932

    		 Carbonic Anhydrase TNF Receptor IFNAR Inflammation/Immunology
    Actarit (4-Acetylaminophenylacetic acid) is an orally active Carbonic Anhydrase II (CAII) inhibitor with an IC50 of 422 nM. Actarit shows suppressive effects experimental autoimmune encephalomyelitis in rats. Actarit inhibits the development of type ll collagen (CII)-induced arthritis in mice by suppressing delayed-type hypersensitivity to CII. Actarit can be used for the study of Multiple Sclerosis (MS) and rheumatoid arthritis .
    Actarit
  • HY-P5003
    Collagen Type II Fragment

    		MMP Inflammation/Immunology
    Collagen Type II Fragment is an anti-inflammatory peptide that potently inhibits collagen-induced arthritis (CIA) in mice. Collagen Type II Fragment can be used for research on inflammation and immunity .
    Collagen Type II Fragment
  • HY-100600
    BGG463

    K03859

    		 CDK Others
    BGG463 (K03859) is an orally active type II CDK2 inhibitor .
    BGG463
  • HY-16742B
    Gepotidacin mesylate hydrate
    10+ Cited Publications

    		 Antibiotic Bacterial Topoisomerase Infection
    Gepotidacin mesylate hydrate is an orally active triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor. Gepotidacin mesylate hydrate inhibits bacterial DNA replication by blocking topoisomerase enzymes. Gepotidacin mesylate hydrate selectively inhibits topoisomerase IV and the B subunit of DNA gyrase .
    Gepotidacin mesylate hydrate
  • HY-122394
    Thiolactomycin

    		Antibiotic Bacterial Fatty Acid Synthase (FASN) Infection
    Thiolactomycin is an orally active bacterial type II fatty acid synthase (FAS-II) inhibitor with antibacterial and antimalarial activities. Thiolactomycin specifically targets KasA/KasB in mycobacteria and FabB/FabF in bacteria, thereby inhibiting the biosynthesis of fatty acids and mycolic acids. Thiolactomycin can be used in studies related to tuberculosis, systemic bacterial infections, and experimental pyelonephritis .
    Thiolactomycin
  • HY-114520
    TT01001

    		Monoamine Oxidase Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    TT01001 is a selective and orally active mitoNEET agonist and a monoamine oxidase B (MAO-B) inhibitor (IC50 = 8.84 μM). TT01001 does not activate PPARγ but interacts with MitoNEET. TT01001 attenuates oxidative stress and neuronal apoptosis by preventing mitoNEET-mediated mitochondrial dysfunction. TT01001 improves type II diabetes and ameliorates mitochondrial function of mice. TT01001 can used for the studies of type II diabetes and neurological disorders .
    TT01001
  • HY-16936
    JH-II-127

    		LRRK2 Neurological Disease
    JH-II-127 is an orally active, highly potent, selective and brain-permeable LRRK2 inhibitor, with IC50s of 6, 2 and 48 nM for wild-type LRRK2 and LRRK2-G2019S and mutant LRRK2-A2016T. JH-II-127 inhibits Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .
    JH-II-127
  • HY-148072
    MM3122

    		SARS-CoV Infection
    MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells .
    MM3122
  • HY-P990187
    Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114)

    		MHC Influenza Virus Infection Inflammation/Immunology
    Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse MHC Class II. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) does not react with I-Af, I-Ak, or I-As haplotypes. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) blocks MHC Class II and inhibit T cell generation. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) can be used for the researches of infection and immunology, such as influenza A virus (IAV) infection .
    Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114)
  • HY-119942
    c-Fms-IN-8

    		c-Fms Cancer
    c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM .
    c-Fms-IN-8
  • HY-P990188
    Anti-Mouse MHC class II (I-A) Antibody (Y-3P)

    		MHC Inflammation/Immunology
    Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse MHC class II. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) reacts with mouse MHC Class II haplotypes I-Ab, I-Af, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, and weakly with I-Ak. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) blocks MHC class II and inhibits expansion of regulate T cells. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) can be used for the immunology research .
    Anti-Mouse MHC class II (I-A) Antibody (Y-3P)
  • HY-103245
    Cl-4AS-1

    		Androgen Receptor Cancer
    Cl-4AS-1, a potent steroidal androgen receptor (AR) agonist (IC50 = 12 nM), is also an inhibitor of 5α-reductase types I and II (IC50 = 6 and 10 nM, respectively) .
    Cl-4AS-1
  • HY-P990189
    Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)

    		MHC Apoptosis Reactive Oxygen Species (ROS) Infection Cancer
    Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .
    Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)
  • HY-122906
    JTE-952

    		c-Fms Inflammation/Immunology
    JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis .
    JTE-952
  • HY-139077
    SCD1 inhibitor-3

    		Stearoyl-CoA Desaturase (SCD) Metabolic Disease Cancer
    SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer .
    SCD1 inhibitor-3
  • HY-108534
    PMX464

    AW 464

    		 TrxR Inflammation/Immunology Cancer
    PMX464 (AW 464), a thiol-reactive quinol, is the inhibitor of thioredoxin-thioredoxin reductase (Trx/TrxR) system. PMX464 can inhibit NF-κB-mediated proinflammatory activation of human type II alveolar epithelial cells .
    PMX464
  • HY-130136A
    TMPRSS6-IN-1 TFA

    		Ser/Thr Protease Others
    TMPRSS6-IN-1 (TFA) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .
    TMPRSS6-IN-1 TFA
  • HY-13635A
    Finasteride acetate

    MK-906 acetate

    		 5 alpha Reductase Cancer
    Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride acetate
  • HY-113767
    Momordin II

    		DNA/RNA Synthesis Metabolic Disease
    Momordin II, an oleanane-type triterpene glycoside, is a ribosome inactivating protein. Momordin II inhibits cell-free protein synthesis, releases adenine from rat liver ribosomes and from DNA, and has no RNase activity .
    Momordin II
  • HY-13635R
    Finasteride (Standard)

    MK-906 (Standard)

    		 Reference Standards 5 alpha Reductase Cancer
    Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride (Standard)
  • HY-114564
    Satigrel

    E5510

    		 Prostaglandin Receptor Cardiovascular Disease
    Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .
    Satigrel
  • HY-13955S
    Telmisartan-d3

    		Angiotensin Receptor Autophagy Cardiovascular Disease Endocrinology
    Telmisartan-d3 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM .
    Telmisartan-d3
  • HY-130136
    TMPRSS6-IN-1

    		Ser/Thr Protease Others
    TMPRSS6-IN-1 (compound 8) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .
    TMPRSS6-IN-1
  • HY-174427
    RN341

    		LRRK2 Neurological Disease
    RN341 is a specific type II kinase inhibitor of LRRK2 (IC50: 296 nM). RN341 inhibits LRRK2 phosphorylation and avoids S935 dephosphorylation by stabilizing the open conformation. RN341 rescues LRRK2-mediated kinesin motility block by preventing microtubule binding. RN341 effectively inhibits LRRK2 wild-type and G2019S mutant at the cellular level. RN341 provides a new direction for Parkinson's disease research.
    RN341
  • HY-137063
    (+)-ITD-1

    		TGF-beta/Smad TGF-β Receptor Cardiovascular Disease
    (+)-ITD-1 is an inhibitor for TGF-β, that inhibits the TGF-β2 with an IC50 of 0.46 μM. (+)-ITD-1 promotes the degradation of TGF-b type II receptor (TGFBR2) and the differentiation of cardiomyocyte, and inhibits the mesoderm formation in the early differentiation stage of mouse embryonic stem cells (mESCs) .
    (+)-ITD-1
  • HY-16742C
    Gepotidacin hydrochloride

    GSK2140944 hydrochloride

    		 Antibiotic Bacterial Topoisomerase Infection
    Gepotidacin hydrochloride is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor.
    Gepotidacin hydrochloride
  • HY-143279
    Topoisomerase II inhibitor 3

    		Topoisomerase Apoptosis Cancer
    Topoisomerase II inhibitor 3 (Compound 6 h ) is a acridone derivatives, as well as a Type II DNA topoisomerase (topo II) inhibitor , as a topo IIα/β inhibitor with the value of IC50 is 0.17 μM for topo IIα and the value of IC50 is 0.23 μM for topo IIβ subtypes, caused obvious DNA damage, and induced apoptosis by triggering the loss of mitochondrial membrane potential .
    Topoisomerase II inhibitor 3
  • HY-14955A
    (Rac)-Managlinat dialanetil

    (Rac)-MB06322; (Rac)-CS-917

    		 Others Others
    (Rac)-Managlinat dialanetil ((Rac)-MB06322) is a compound for the inhibition of type 2 diabetes that is in Phase II clinical trials and works by inhibiting gluconeogenesis.
    (Rac)-Managlinat dialanetil
  • HY-16742R
    Gepotidacin (Standard)

    GSK2140944 (Standard)

    		 Reference Standards Antibiotic Bacterial Topoisomerase Infection
    Gepotidacin (Standard) is the analytical standard of Gepotidacin. This product is intended for research and analytical applications. Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor.
    Gepotidacin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: